XXXX in lung transplant recipients: experience of a tertiary hospital and literature review.

@entity1 @entity5 @entity2 @entity2416 @entity1030 @entity401 @entity454
BACKGROUND: Lung transplantation is a viable therapy for @entity1 with @entity454 and is being increasingly performed worldwide. The incidence of @entity2 after lung transplantation has increased concomitantly, although data are still sparse. METHODS: The computerized medical records of the Pulmonary Institute of a tertiary care medical center were searched for @entity1 who underwent lung transplantation from 1997 to 2009 and acquired @entity2 postoperatively. The prevalence, potential contributing factors, and outcome of @entity5 were determined, and the medical literature was reviewed. RESULTS: @entity5 developed in 7 of the 290 lung transplant recipients (2.4%). All had received a single lung transplant and in most cases, the @entity5 developed in the native lung. These findings were similar to reports in the literature. The indication for transplantation was @entity1030 or @entity2416 / @entity401 . All had a history of smoking. The average interval from transplantation to development of @entity2 was 5 years (range 1-9). Five @entity1 had stage 4 @entity5 at diagnosis and 2 had stage 1. Six @entity1 died from 10 days to 1 year after diagnosis. CONCLUSION: Lung transplantation is associated with a relatively high prevalence of @entity5 , particularly in the native lung, in @entity1 with primary @entity1030 / @entity2416 , and a history of smoking. The @entity5 is usually diagnosed at an advanced stage with poor outcome. Efforts to improve screening are recommended, as aggressive management and treatment may be beneficial for earlier stage disease.
